3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Terminated
1
Active not recruiting
1
Sponsor Class
OTHER
2
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
7
Other hematologic neoplasm
3
Dermatologic
2
CNS
2
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Uveal Melanoma
1
Glioma
1
Glioblastoma
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Interventions
Temozolomide
123
Radiotherapy
47
Bevacizumab
46
Lomustine
25
Radiation
20
Nivolumab
17
Irinotecan
16
Carboplatin
16
Cyclophosphamide
14
Granulocyte-Macrophage Colony-Stimulating Factor
13
pembrolizumab
11
dabrafenib
10
Trastuzumab
10
Surgical Procedures, Operative
10
Capecitabine
10
paclitaxel-Angiopep-2 conjugate
8
TIC10 compound
8
Paclitaxel
8
Gemcitabine
8
Carmustine
8
trametinib
7
Topotecan
7
IL13-PE38
7
Everolimus
7
Drug Therapy
7
Aminolevulinic Acid
7
AZD 6244
7
3-Iodobenzylguanidine
7
fludarabine
6
enzastaurin
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
ADI PEG20
×
CNS
×
Clear all
NCT04587830
2025-08-26
GBM
Polaris Group
Phase 2
Active not recruiting
100 enrolled
NCT02029690
2020-09-25
TRAP
Polaris Group
Phase 1
Terminated
85 enrolled